Market news

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.

ResMed (RMD) stock gains as RBC Capital Markets upgrades the company to Outperform and hikes target to $262, citing positives in its Q4 FY26 results. Read more here.

ResMed (RMD) is projected to attain high-single-digit EPS growth over the next three years, despite

ResMed (RMD) has an average rating of overweight and mean price target of $262.82, according to anal

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers.

Michael J. Farrell, Director, Chairman and CEO, on September 08, 2026, sold 4,991 shares in Resmed (

ResMed (RMD) has an average rating of overweight and mean price target of $262.07, according to anal

ResMed (RMD) has an average rating of overweight and mean price target of $260.24, according to anal

Although ResMed has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]

ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management attributed the margin compression primarily to higher R&D and supply chain costs amid inflation, despite continued demand for sleep devices and masks. CEO Mick Farrell pointed to ongoing investments in innovation and supply chain efficiency as both a necessity and a source of margin challenges. Additionally, ResMed took a $42 million charge

Detailed price information for Resmed Inc (RMD-N) from The Globe and Mail including charting and trades.

Detailed price information for Resmed Inc (RMD-N) from The Globe and Mail including charting and trades.

In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...

Detailed price information for Resmed Inc (RMD-N) from The Globe and Mail including charting and trades.

Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.

US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.